Showing results (1-10 of 25) with videos related to
Sort By:
Pageof 3
Journal of Cardiovascular Pharmacology|July 30, 2019
Successful COMPASS, Disappointing COMMANDER HF, What Have We Learned From These Two Trials?Yuhu He, Xinqun Hu, Shenghua ZhouScientific Reports|September 29, 2025
Red blood cell distribution width and mortality in chronic obstructive pulmonary disease patients with acute respiratory failure: a retrospective studyKe Yu, Anjian Gao, Yuhu He, et al.Journal of Hypertension|September 17, 2024
Increased levels of urine volatile organic compounds are associated with hypertension riskXialei Zheng, Pu Zou, Cheng Zeng, et al.Respiratory Research|November 2, 2023
Prostaglandin and prostaglandin receptors: present and future promising therapeutic targets for pulmonary arterial hypertensionCheng Zeng, Jing Liu, Xialei Zheng, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 12, 2023
HMGB family proteins: Potential biomarkers and mechanistic factors in cardiovascular diseasesXialei Zheng, Junmi Lu, Jing Liu, et al.International Immunopharmacology|April 23, 2023
Inflachromene inhibits intimal hyperplasia through the HMGB1/2- regulated TLR4-NF-κB pathwayShuai Teng, Zhaowei Zhu, Chenkai Wu, et al.Diabetes, Obesity & Metabolism|May 28, 2025
Fully automated insulin delivery systems in type 1 diabetes: A systematic review and meta-analysisWenqi Fan, Chao Deng, Ruoyao Xu, et al.Circulation. Cardiovascular Genetics|January 13, 2017
Osteoprotegerin Disruption Attenuates HySu-Induced Pulmonary Hypertension Through Integrin αvβ3/FAK/AKT Pathway SuppressionDaile Jia, Qian Zhu, Huan Liu, et al.Cardiovascular Research|April 14, 2017
RAGE-mediated extracellular matrix proteins accumulation exacerbates HySu-induced pulmonary hypertensionDaile Jia, Yuhu He, Qian Zhu, et al.Acta Diabetologica|February 21, 2024
Elevated serum levels of leukocyte cell-derived chemotaxin 2 are associated with the prevalence of metabolic syndromeXialei Zheng, Junmi Lu, Shaojun Xiang, et al.Pageof 3